Katrina Thornber

London

Editorial Assistant at EMJ- European Medical Journal

Featured in: Favicon

emjreviews.com

Articles

Combination Therapy Improves Outcomes in Prostate Cancer

2 weeks ago | emjreviews.com | Katrina Thornber

ENZALUTAMIDE, an oral androgen receptor inhibitor, has demonstrated significant clinical benefit in men with metastatic hormone-sensitive prostate cancer (mHSPC), particularly when used in combination with androgen deprivation therapy (ADT). Findings from the pivotal ARCHES trial revealed that enzalutamide plus ADT significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) compared to placebo plus ADT.
Brensocatib Reduces Exacerbations in Patients with Bronchiectasis

2 weeks ago | emjreviews.com | Katrina Thornber

A ONCE-daily oral therapy targeting neutrophilic inflammation has shown promise in reducing exacerbations in patients with bronchiectasis, according to results from a large Phase 3 trial. The double-blind, randomised study enrolled 1,721 patients, including 1,680 adults and 41 adolescents, and allocated them to receive either 10 mg or 25 mg of brensocatib, or placebo.
EuroPCR 2025: 10-year Results of the DANAMI-3-PRIMULTI Trial

2 weeks ago | emjreviews.com | Katrina Thornber

FFR-guided complete revascularisation reduces long-term repeat cardiovascular events compared with infarct-related artery only treatment in patients with STEMI and multivessel disease, according to the 10-year results of the DANAMI-3-PRIMULTI trial presented at EuroPCR 2025. The optimal long-term strategy for managing patients presenting with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease remains a subject of ongoing debate.
Seasonal Allergy Symptoms Improved With New Biologic Treatment

2 weeks ago | emjreviews.com | Katrina Thornber

SEASONAL allergic rhinitis (SAR), a common yet often debilitating condition, is triggered by airborne allergens and marked by intense nasal inflammation. Unlike perennial allergic rhinitis (PAR), SAR presents more severe symptoms and has proven more difficult to manage, especially as climate change threatens to exacerbate pollen levels and extend allergy seasons.
EuroPCR 2025: Routine Embolic Protection Not Effective for Stroke Prevention in TAVI

2 weeks ago | emjreviews.com | Katrina Thornber

ROUTINE use of cerebral embolic protection (CEP) devices during transcatheter aortic valve implantation (TAVI) does not reduce the risk of periprocedural stroke, according to a meta-analysis of individual patient data from the PROTECTED TAVR and BHF PROTECT-TAVI trials presented at EuroPCR 2025. Stroke remains a significant complication following TAVI for severe aortic stenosis, with embolisation of debris during the procedure being a primary cause.
EuroPCR 2025: FFR-Guided PCI Lowers Complications After TAVI

2 weeks ago | emjreviews.com | Katrina Thornber

FRACTIONAL flow reserve (FFR)-guided percutaneous coronary intervention (PCI) significantly reduced major adverse cardiac and cerebrovascular events at 12 months compared to angiography-guided PCI in patients with intermediate coronary artery disease (CAD) undergoing transcatheter aortic valve implantation (TAVI). This finding comes from the FAITAVI randomised trial, recently presented at EuroPCR 2025 in Paris, France.
EuroPCR 2025: Less Bleeding after PCI with Short DAPT and Prasugrel in Acute Coronary Syndrome

2 weeks ago | emjreviews.com | Katrina Thornber

A one-month course of dual antiplatelet therapy (DAPT) followed by reduced-dose prasugrel monotherapy significantly reduced bleeding events without increasing ischaemic risk compared to standard 12-month DAPT in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), according to the 4D-ACS randomised trial, presented at EuroPCR 2025 in Paris, France.
Side Effects in Bladder Cancer Treatment Worse Than Estimated

4 weeks ago | emjreviews.com | Katrina Thornber

A RECENT study has revealed significant discrepancies between clinician- and patient-reported symptom severity in individuals with locally advanced or metastatic urothelial carcinoma (la/mUC) treated with pembrolizumab. Pembrolizumab, an immune checkpoint inhibitor, is a standard second-line therapy for this cancer type, but its side effects, often immune-related, can escalate quickly and impact patient wellbeing.
Cytisinicline Proves Potent and Safe for Quitting Smoking

4 weeks ago | emjreviews.com | Katrina Thornber

A NEW Phase III trial has strengthened the evidence supporting cytisinicline as an effective and well-tolerated medication for smoking cessation, offering renewed hope for clinicians seeking pharmacological tools to combat nicotine addiction. Conducted between January 2022–March 2023 across 20 USA sites, the ORCA-3 trial randomised 792 adult daily smokers (≥10 cigarettes/day) into three groups.
Robotic Baby Mimics Real Feeding Behaviours for Medical Innovation

4 weeks ago | emjreviews.com | Katrina Thornber

A SOFT robotic infant known as BabyBot has been developed to accurately mimic feeding behaviours and oral motor development in human infants from birth to six months old, offering a new, non-invasive platform for research and innovation in paediatric care134. The challenge of studying infant feeding arises from the ethical and practical limitations of direct testing on babies, particularly when invasive procedures are required.